secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001370053-23-000054
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio reports positive Phase 3 GEMINI-1 trial for imsidolimab in GPP; 53.3% vs 13.3% placebo at Week 4
--------------------------------------------------------------------------------

- 53.3% of imsidolimab-treated patients achieved GPPPGA 0/1 at Week 4 vs 13.3% placebo (p=0.0131).
- No SAEs or severe AEs in imsidolimab-treated patients; low infection rate vs placebo.
- Only 3.3% had detectable non-neutralizing ADA.
- Plans to file BLA with FDA by Q3 2024 and out-license imsidolimab in 2024.
- Comprehensive data from GEMINI-1 and top-line GEMINI-2 expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/0001370053-23-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/anab-20231009.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer